Diaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share Capital

Diaceutics ( (GB:DXRX) ) just unveiled an announcement.

Diaceutics PLC has reported routine share purchases under its UK and Global Share Incentive Plan, with trustees acquiring ordinary shares on behalf of senior executives Susanne Munksted, Jordan Clark and Nick Roberts. Under the schemes, each employee purchase is matched 1:1 by a conditional share award, with these awards for UK participants settled using previously allotted but unallocated shares held in trust.

The transactions, which will continue monthly until further notice, do not change Diaceutics’ total shares in issue, which remain at 84,917,283. As a result, there is no impact on the company’s overall share capital or voting rights, but the programme reinforces long-term alignment between management, employees and shareholders through ongoing equity participation.

The most recent analyst rating on (GB:DXRX) stock is a Sell with a £159.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

Spark’s Take on DXRX Stock

According to Spark, TipRanks’ AI Analyst, DXRX is a Neutral.

Diaceutics’ strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock’s valuation is also concerning due to negative earnings.

To see Spark’s full report on DXRX stock, click here.

More about Diaceutics

Diaceutics PLC is a technology and solutions provider to the pharma and biotech industry, focused on enabling precision medicine. The company offers an end-to-end commercialisation platform for precision therapies, combining data analytics with scientific and advisory services via its DXRX – The Diagnostics Network platform.

Average Trading Volume: 134,648

Technical Sentiment Signal: Buy

Current Market Cap: £127.3M

For an in-depth examination of DXRX stock, go to TipRanks’ Overview page.